StemCells (NASDAQ: STEM) announced that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Cantor Fitzgerald Expects StemCells (STEM) to Present GA Data This Week; Reiterates Buy June 22, 2015 7:03 AM StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health CanadaJune 18, 2015 8:05 AM StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health CanadaJune 18, 2015 8:05 AM